Phase 1 × Recruiting × Triple Negative Breast Neoplasms × Clear all Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Phase 1 Recruiting
57 enrolled
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
Phase 1 Recruiting
32 enrolled
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Phase 1 Recruiting
36 enrolled
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Phase 1 Recruiting
52 enrolled
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Phase 1 Recruiting
180 enrolled
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1 Recruiting
162 enrolled
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
205 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Phase 1 Recruiting
110 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1 Recruiting
258 enrolled
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 Recruiting
150 enrolled
DELTA-101
Phase 1 Recruiting
396 enrolled
A Study of LY4175408 in Participants With Advanced Cancer
Phase 1 Recruiting
240 enrolled
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Phase 1 Recruiting
70 enrolled
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Phase 1 Recruiting
90 enrolled
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 Recruiting
714 enrolled
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
Phase 1 Recruiting
80 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Phase 1 Recruiting
150 enrolled
EXCEED
Phase 1 Recruiting
490 enrolled
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
150 enrolled
ASTEROID
Phase 1 Recruiting
61 enrolled
DecipHER
Phase 1 Recruiting
30 enrolled
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Phase 1 Recruiting
470 enrolled
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Phase 1 Recruiting
18 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
PAveMenT
Phase 1 Recruiting
45 enrolled
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Phase 1 Recruiting
495 enrolled
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Phase 1 Recruiting
60 enrolled
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Phase 1 Recruiting
18 enrolled
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
145 enrolled
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
260 enrolled
ON-5001
Phase 1 Recruiting
168 enrolled
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
Phase 1 Recruiting
12 enrolled
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 Recruiting
73 enrolled
A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
Phase 1 Recruiting
30 enrolled
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Phase 1 Recruiting
512 enrolled
A Study of XMT-1660 in Participants With Solid Tumors
Phase 1 Recruiting
319 enrolled
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Phase 1 Recruiting
149 enrolled
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
260 enrolled
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Phase 1 Recruiting
130 enrolled
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Phase 1 Recruiting
42 enrolled
A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 Recruiting
345 enrolled
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 Recruiting
40 enrolled
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Phase 1 Recruiting
12 enrolled
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Phase 1 Recruiting
30 enrolled
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
Phase 1 Recruiting
12 enrolled
PRE-I-SPY-PI
Phase 1 Recruiting
124 enrolled
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Phase 1 Recruiting
33 enrolled
A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Phase 1 Recruiting
70 enrolled